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Abstract Establishing a diagnosis in patients with a
suspected mitochondrial disorder is often a challenge. Both
knowledge of the clinical spectrum of mitochondrial
disorders and the number of identified disease-causing
molecular genetic defects are continuously expanding. The
diagnostic examination of patients requires a multi-
disciplinary clinical and laboratory evaluation in which
the biochemical examination of the mitochondrial function-
al state often plays a central role. In most cases, a muscle
biopsy provides the best opportunity to examine mitochon-
drial function. In addition to activity measurements of
individual oxidative phosphorylation enzymes, analysis of
mitochondrial respiration, substrate oxidation, and ATP
production rates is performed to obtain a detailed picture of
the mitochondrial energy-generating system. On the basis
of the compilation of clinical, biochemical, and other
laboratory test results, candidate genes are selected for
molecular genetic testing. In patients in whom an unknown
genetic variant is identified, a compatible biochemical
phenotype is often required to firmly establish the diagno-
sis. In addition to the current role of the biochemical
analysis in the diagnostic examination of patients with a
suspected mitochondria disorder, this report gives a future
perspective on the biochemical diagnosis in view of both
the expanding genotypes of mitochondrial disorders and the
possibilities for high throughput molecular genetic diagnosis.
Introduction
Mitochondrial disorders are a clinically heterogeneous
group of disorders that are caused by defects in the
mitochondrial ATP production system. The previously
published guidelines and diagnostic criteria for mitochon-
drial disorders illustrate the challenges of diagnosing
patients with a suspected mitochondrial disorder (Bernier
et al. 2002; Haas et al. 2008; Morava et al. 2006; Thorburn
and Smeitink 2001; Walker et al. 1996; Wolf and Smeitink
2002). Given the extremely broad clinical spectrum and the
relatively poor genotype–phenotype correlation of mito-
chondrial genetic defects, it is usually preferred to perform
a complete laboratory diagnostic work-up, and to evaluate
the results in the context of the clinical phenotype and
family history of the patient (Haas et al. 2007; Kirkman et
al. 2008; Zeviani and Di Donato 2004). Laboratory
diagnostic analysis of patients with a suspected mitochon-
drial disorder is a multi-disciplinary approach involving a
broad spectrum of laboratory tests, including metabolite
analysis, enzymatic measurements, and molecular genetic
analysis (Haas et al. 2008). In a minority of cases, those
with a well-recognized phenotype, it might be possible to
shortcut the diagnostic process and go directly to molecular
genetic analysis (Finsterer et al. 2009). Although time- and
cost-effective when successful, there are drawbacks to this
approach. Importantly, there is a chance of finding a
mutation that is irrelevant to the pathogenesis of the disease
of the patient. It has been shown that the prevalence of
pathogenic mtDNA mutations is at least 1 in 200, (Elliott et
al. 2008), while the prevalence of mtDNA diseases or of
being at risk to develop an mtDNA disease has been
estimated to be around 1 in 10,000 and 1 in 6,000,
respectively (Schaefer et al. 2008). Establishing the
biochemical phenotype is not only important for candidate
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gene selection but also provides important information that
may be required to interpret genetic test results. For these
and other reasons, as outlined below, the biochemical
examination of a muscle biopsy to evaluate the functional
state of mitochondria is still regarded as the cornerstone of
the diagnostic examination of patients with a suspected
mitochondrial disease.
Metabolite analysis
Prior to the biochemical examination of a muscle biopsy,
metabolite analysis in blood and urine is usually performed.
The results often provide important clues for the presence
of a mitochondrial defect and, in some cases, can even give
some indications for the location of the primary cause of
the disease. Defects in the mitochondrial energy-generating
system may lead to high lactate levels in blood, urine, and/
or CSF due to reduced pyruvate utilization by the
mitochondria. In the case of a respiratory chain defect, the
lactate/pyruvate ratio in blood will increase because of a
shift in the mitochondrial redox state (Trijbels et al. 1988).
This will also affect the ratio of the ketone bodies 3-OH-
butyrate and acetoacetate. In the case of a pyruvate
dehydrogenase defect, the ratio between lactate and
pyruvate may be normal while both metabolites are
elevated. However, these features are neither very specific
nor sensitive for use as a diagnostic test. Amino acid
analysis can reveal elevated alanine, as a product of the
transamination of pyruvate by alanine aminotransferase.
Elevated levels of the branched chain amino acids could be
an indication for an E3 deficiency; an enzyme module
shared by the branched chain amino acid dehydrogenase, 2-
oxoglutarate dehydrogenase, and pyruvate dehydrogenase.
Generalized amino aciduria is sometimes seen as a result of
renal tubulopathy caused by mitochondrial defects. Urine
organic acids of mitochondrial patients may show increased
lactate excretion. In addition, increased levels of TCA cycle
intermediates, such as malate, succinate, 2-oxoglutarate,
and fumarate can be found. A high level of fumarate
excretion is an indication for fumarase deficiency. Elevated
2-oxoglutarate excretion is seen in patients with a 2-
oxoglutarate deficiency, but also in other mitochondrial
defects. Elevated levels of several other metabolites can be
found in mitochondrial patients, including ethylmalonate,
sometimes seen in respiratory chain deficient patients but
also in SCAD, MADD, and in ETHE1 defects, methyl-
malonate, e.g., in succinate-CoA ligase deficiency (Carrozzo
et al. 2007), and 3-methylglutaconate (3-MG). Four types of
3-MG acidurias can be discriminated, including the
classical 3-MGA hydratase deficiency (type I MGA), Barth
syndrome (type II; TAZ defect), Costeff syndrome (type III;
OPA1 defect), and the group of type IV MGAs which
includes several mitochondrial disorders, such as those due
to genetic defects in POLG, SUCLA2, and TMEM70
(Wortmann et al. 2009). In addition, this group contains
patients with MEGDEL (3-methylglutaconic aciduria,
sensory-neural deafness, encephalopathy, and Leigh-like
syndrome) association (Wortmann et al. 2006).
Enzyme measurements
Biochemical diagnostic examination of tissue and cell
samples from mitochondrial patients includes measurements
of enzyme activities of the oxidative phosphorylation
(OXPHOS) system, consisting of complex I (EC 1.6.5.3),
complex II (EC 1.3.5.1), complex III (EC 1.10.2.2), complex
IV (EC 1.9.3.1), and complex V (EC 3.6.1.3) (Fig. 1). Assays
to quantify OXPHOS enzyme activities are usually based on
spectrophotometry (Benit et al. 2006; Janssen et al. 2007;
Kirby et al. 2007; Rustin et al. 1994). Table 1 gives an
overview of the assays that are currently operational in our
center. Alternatively, or in addition, assays that determine the
amounts of OXPHOS complexes are performed, such as
Blue Native gel electrophoresis followed by western blot
analysis (Schagger and von Jagow 1991). A drawback of the
latter approach could be that catalytic defects can be missed,
although for complex I it has been shown that there is often a
correlation between residual enzyme activities and the
amounts of holo-complex I (Koopman et al. 2008). Another
way to examine OXPHOS enzymes is by colorimetric in-gel
measurements of enzyme activities after blue-native gel
electrophoresis, or other colorimetric assays based on a
similar principle (Van Coster et al. 2001; Willis et al. 2009;
Wittig et al. 2007; Zerbetto et al. 1997). For complex I, these
assays makes use of an electron acceptor that changes color
upon reduction (e.g., nitrotetrazolium blue), instead of
analogues of the natural substrate coenzyme Q that are used
in spectrophotometric complex I assays (Benit et al. 2006;
Janssen et al. 2007; Kirby et al. 2007). This means that the
colorimetric assay measures only the activity of the NADH
dehydrogenase module of complex I, instead of the entire
NADH:ubiquinone oxidoreductase activity that is measured
in spectrophotometric assays. Moreover, in-gel activity
assays are not designed to provide highly quantitative
information, and therefore mild deficiencies of OXPHOS
enzymes may be difficult to detect. This also holds true for
other gel-based assays to quantify enzyme activities or
amounts, such as western blot assays. Therefore, most
diagnostic centers prefer to make use of spectrophotometric
enzyme assays. At this moment, there is no universal assay
design for spectrophotometric quantification of OXPHOS
enzyme activities. Different assay protocols are in use in
different laboratories. Assays differ with respect to buffer
conditions, reaction temperatures, substrate concentrations,
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and other assay ingredients, such as bovine serum albumin or
salts. Nevertheless, for most of these assays, the principles
on which the different protocols are based are similar. The
use of different assay protocols can make an inter-laboratory
comparison of test results difficult. For both ethical and
practical reasons, a quality control scheme involving the
analysis of patient-derived material, including tissue samples
with OXPHOS deficiencies, seems impossible. Indeed,
attempts to perform a laboratory quality assessment have
been hampered by the limited availability of patient-derived
muscle samples, and therefore have been done with animal
muscle tissue (Gellerich et al. 2004; Medja et al. 2009).
Despite the different assay protocols, as each laboratory has
established its own reference ranges to which diagnostic test
results are related, it is questionable if the use of different
assay protocols could be a major cause for possible
misdiagnoses.
The interpretation of enzymatic measurements is not as
straightforward as for many other metabolic enzyme
disorders. For the OXPHOS enzymes, there is a only a
small margin between patient ranges and control ranges
(Rustin et al. 1994). Therefore, activities around the lowest
reference value cannot always be considered as definite
























Fig. 1 Schematic representation of the mitochondrial energy gener-
ating system. Substrates are shuttled into mitochondria and are
metabolized in the matrix in the TCA cycle, during which reduction
equivalents NADH and FADH2 are formed. These are oxidized by
complex I (CI) and II (CII) of the respiratory chain, and electrons
coming from NADH and FADH2 are shuttled through complexes I or
II, coenzyme Q, complex III (CIII), cytochrome c, and complex IV
(CIV) to molecular oxygen. During the electron transport process,
protons are pumped out of the mitochondrial matrix to the
intermembrane space by complexes I, III, and IV. The electrochemical
gradient thus formed is used by complex V (CV; F1/F0 ATPase) to
convert ADP into ATP. The intramitochondrial ATP/ADP ratio is
balanced by shuttling ADP and ATP in and out of the mitochondrial
matrix by the adenosine nucleotide transporter ANT (not shown here).
For diagnostic purposes, the mitochondrial energy generating system
can be analyzed in several ways. By using 14C labeled pyruvate,
malate, or succinate, the conversion rates of these substrates can be
determined by measuring the amounts of released 14CO2 as
parameters for the overall capacity of the mitochondrial energy-
generating system (Janssen et al 2006). A similar parameter is the
oxygen consumption rate in the presence of different substrates, e.g.,
pyruvate + malate, and which can be measured by respirometry or by
fluorescent probes (Jonckheere et al 2010; Rustin et al 1994). The rate
of synthesis of the end product ATP in the presence of different
mitochondrial substrates is also representative for the capacity of the
mitochondrial energy-generating system (Janssen et al 2006). In
addition to these flux-parameters of the mitochondrial energy-
generating system, individual enzymes can be determined by
spectrophotometric and radiochemical assays
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as mentioned before, additional observations (mtDNA
sequence, metabolites, clinical features, etc.) should be
included in the evaluation of the enzyme test results. It can
be hypothesized that one of the reasons for this problem is
the complexity of the OXPHOS enzymes, which are multi-
subunit enzymes encoded by both mitochondrial and
nuclear genomes, except for complex II, which exclusively
consists of nuclear encoded subunits. It seems likely that
the genetic make-up of the entire OXPHOS system and of
the individual complexes could modulate the effect of
single subunit mutations. As there is no universal correla-
tion between the severity of the enzyme deficiency and the
severity of the clinical phenotype, detection of even very
mild deficiencies is very important. Ratios between
mitochondrial enzymes give a much narrower range of
normal values compared to activities expressed on the basis
of protein content of the sample (Rustin et al. 1991). Often,
citrate synthase is used as a reference enzyme, although
ratios between OXPHOS enzymes and tricarboxylic acid
(TCA) cycle enzymes are less constant compared to ratios
within the OXPHOS system (Rustin et al. 1991). Further-
more, a moderate increase of the activity of citrate synthase
is frequently observed in tissues with an OXPHOS
deficiency. For neonates, results should be interpreted very
cautiously as it has been shown that there are age-
dependent differences in OXPHOS enzyme activities in
very early childhood (Honzik et al. 2008; Sperl et al. 1992).
Table 2 gives an overview of the results of the biochemical
diagnostics in Nijmegen for 2009. This shows that complex
I and IV deficiencies are the most frequently encountered
OXPHOS deficiencies. In addition to single OXPHOS
enzyme measurements, combinations of enzymes can be
measured. For complex I, an additional measurement of
complex I + complex III (NADH:cytochrome c oxidore-
ductase) can be performed. This activity is reduced in the
case of a complex I deficiency. In addition, as this is a
coenzyme Q-dependent reaction, this activity is also
reduced in the case of a CoQ biosynthesis defect. Similarly,
the activity of complex II + III is also coenzyme Q-
dependent and reduced in the case of a CoQ deficiency.
Further indications for a CoQ deficiency can be obtained by
addition of a CoQ analogue to the complex II + III enzyme
Table 1 Overview of the assays currently in use in the Nijmegen Center for mitochondrial disorders
Enzyme Substrate Assay conditions Read-out
Complex I 0.2 mmol/L NADH 25 mM phosphate buffer, pH 7.6 1 µmol/L rotenone-sensitive
DCIP reduction at 600 nm70 µmol /L coenzyme Q1 0.35% BSA
60 µmol/L DCIP
Complex II 10 mmol/L succinate 80 mM phosphate buffer, pH 7.8 5 mmol/L malonate-sensitive




0.3 mmol/L sodium azide
Complex III 300 µmol/L decylubiquinol 50 mM phosphate buffer, pH 7.8 Cytochrome c reduction at 550 nm
50 µmol/L cytochrome c 1.0 mmol/L EDTA
3.0 mmol/L sodium azide
0.04% Tween20
Complex IV 70 µmol/L reduced cytochrome c 30 mM phosphate buffer, pH 7.4 Cytochrome c oxidation at 550 nm
Complex V 3 mmol/L ATP 25 mM phosphate buffer, pH 8.0 10 µmol/L oligomycin-sensitive







2.5 U/ml lactate dehydrogenase
1.5 U/ml pyruvate kinase
The assays are performed at 37°C. The samples that are tested with these assays include isolated mitochondria from muscle and fibroblasts. In
addition, more crude preparations from muscle, such as 10% homogenates in SETH-buffer (Janssen et al 2006), and the 600-g supernatants of
these homogenates, are measured in this way. Extracts from heart, liver, brain, and chorionic villi are examined in a similar manner. These assays
can be performed on any spectrophotometric device that has sufficient sensitivity.
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assay, which will result in normalization of the activity in
the case of a CoQ deficiency (Lopez et al. 2006; Rahman et
al. 2001). Both the combined complex I + III activity and
the II + III activity are less sensitive to detect complex III
deficiencies, so these assays are not a good substitute for
complex III measurements and should only be used to
obtain additional evidence for deficiencies of complex I, II,
or coenzyme Q (Taylor et al. 1993). Coenzyme Q can also
be measured directly by HPLC in muscle, blood, or other
sample types (Duncan et al. 2005). In addition to the
OXPHOS enzymes, activities of pyruvate dehydrogenase or
TCA cycle enzymes can be considered in the case of a
suspected mitochondrial disorder (Bonnefont et al. 1992;
Carrozzo et al. 2007; Reisch and Elpeleg 2007; Zinn et al.
1986). A particular feature of defects in the TCA cycle
enzyme succinate-CoA ligase is depletion of mtDNA
(Carrozzo et al. 2007; Ostergaard et al. 2007; Reisch and
Elpeleg 2007). Patients with a defect in this enzyme often
display a characteristic combination of clinical features,
including early hypotonia, dystonia, and sensori-neuronal
deafness (Morava et al. 2009; Ostergaard et al. 2010). The
mechanism leading to mtDNA depletion in succinate-CoA
ligase deficiency is poorly understood. It is assumed that it
involves the mitochondrial deoxynucleotide salvage en-
zyme nucleoside diphosphate kinase, which has been
shown to physically interact with succinate-CoA ligase
(Kavanaugh-Black et al. 1994). As a consequence of
mtDNA depletion, patients with mutations in the succi-
nate:CoA ligase α-subunit SUCLA2 or β-subunit SUCLG1
can show deficiencies of OXPHOS enzymes complexes I,
III, and IV in muscle tissue.
Which tissue to investigate?
In the majority of mitochondrial patients, skeletal muscle is
affected. Muscle is mitochondria-rich tissue and has a high
energy demand. Therefore, a muscle biopsy provides an
optimal opportunity to detect possible aberrations in the
functional state of mitochondria. The biochemical analysis
of muscle mitochondria can be performed on frozen or on
freshly collected muscle tissue. It should be noted that
analysis of complex V in frozen muscle tissue is considered
to be less reliable than in fresh muscle tissue (Kirby et al.
2007). For optimal preservation of mitochondrial enzymes,
it is important to snap-freeze the sample immediately after
collection. A fresh muscle sample needs to be collected in
cooled (not frozen) transport buffer and should be pro-
cessed within 2–3 h after collection (Janssen et al. 2003).
Fresh muscle has the advantage that, in addition to the
measurement of individual mitochondrial enzymes, mea-
surements on the entire mitochondrial energy-generating
system (MEGS) can be performed (Fig. 1). These measure-
ments can include the analysis of mitochondrial oxygen
consumption in the presence of different combinations of
mitochondrial substrates, such as pyruvate, malate, and
glutamate (Rustin et al. 1994; Will et al. 2006). Alterna-
tively, the oxidation rates of radio-labeled substrates can be
determined, such as the decarboxylation of radio-labeled
pyruvate in the presence of non-labeled co-substrates
(Janssen et al. 2006). In addition, the ATP production rate
in intact mitochondria can be determined as a measure for
the MEGS capacity (Janssen et al. 2006). By examining the
MEGS in the presence of different combinations of
substrates, co-substrates, co-factors, and inhibitors, a
detailed picture of the MEGS is obtained, providing
important clues for the location of the primary mitochon-
drial defect. For example, a reduced pyruvate oxidation rate
in the presence of malate, combined with a normal to
mildly reduced pyruvate oxidation rate in the presence of
carnitine is an indication for an OXPHOS defect (Hoefs et
al. 2008; Jonckheere et al. 2008), while equally reduced
Table 2 Overview of the results of mitochondrial biochemical








Combination of enzymes 7
ATP production (normal OXPHOS) 13
The table gives the percentage of fresh muscle samples that showed an
activity below the lowest control value. Results from frozen muscle
samples are not included in this table. In total, 1,406 fresh muscle
samples were examined in Nijmegen in 2005–2009. Of these, 39%
showed a reduced rate of ATP production from the oxidation of
pyruvate and malate. Approximately 2/3 of the samples with a reduced
ATP production rate also showed a reduced activity of one or more
OXPHOS enzymes. The remaining 1/3 showed normal OXPHOS
enzyme activities. Approximately 5% of this latter group had a
reduced PDHc activity. The figures presented here are similar to those
reported in 2000, only in that case complex V and ATP production
were not included (Loeffen et al. 2000). The reason for a reduced ATP
production rate in the remaining 30% of the patients with normal
OXPHOS and PDHc enzyme activities is either a secondary
mitochondrial dysfunction or an unknown mitochondrial defect, such
as enzymes and transporters for which a diagnostic assay is not (yet)
available. The possibility of unknown defects is quite likely, given the
total number of proteins/genes involved in mitochondrial energy
metabolism and given the fact that new mitochondrial defects are still
being discovered very regularly. This table should not be regarded as
illustrative for the total group of patients with a suspected mitochon-
drial disorder, as not all patients have been tested for enzyme activities
in muscle. Moreover, samples were received from many different
hospitals in different countries, and the indications for doing a muscle
biopsy are not the same in each hospital.
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rates of both types of pyruvate oxidations are an indication
for a pyruvate dehydrogenase complex (PDHc) deficiency
(Janssen et al. 2006). This is not trivial, as in several patients
with a complex I deficiency in muscle tissue, a mild,
secondary PDHc deficiency has been observed (unpublished
observations, and Loeffen et al. 1998; van den Heuvel et al.
1998). Reduced pyruvate oxidation rates have also been
observed in a mitochondrial pyruvate transport defect
(Brivet et al. 2003). Reduced glutamate + malate oxidation
rates have been seen in muscle of patients with glutamate
carrier deficiencies (Molinari et al. 2005; Wibom et al.
2009). A reduced pyruvate oxidation rate that is normalized
by addition of an uncoupler, such as FCCP, indicates a
defect in complex V, the adenine nucleotide translocator, or
the phosphate transporter (Jonckheere et al. 2008; Mayr et
al. 2007). The MEGS assays described above not only
provide in-depth information on the mitochondrial func-
tional state, it has also been shown that these assays are
more sensitive to detect mitochondrial defects, compared to
measurements of individual OXPHOS enzyme activities
(Janssen et al. 2008). In the case of a patient with a clinical
phenotype with profound involvement of tissues other than
muscle, a biopsy of the affected tissue should be consid-
ered. Many cases have been described in which the
diagnostic examination of a heart or liver biopsy has lead
to the diagnosis (Garcia-Cazorla et al. 2006; Taylor et al.
2003). For example, for the mtDNA depletion syndromes
with predominant liver involvement, e.g., due to defects in
MPV17, DGUOK, or POLG (Mandel et al. 2001; Spinazzola
et al. 2006; Van Goethem et al. 2004), a liver biopsy is often
more informative than a muscle biopsy.
Cultured fibroblasts
When a tissue biopsy is performed, it is important to collect
a skin biopsy at the same time, to obtain fibroblasts for
possible additional biochemical and genetic studies. In
addition to the added value of fibroblasts in the diagnostic
evaluation of patients, fibroblasts can be stored and retested
when desired, e.g., when new diagnostic possibilities
emerge in the future. There are several other benefits of
fibroblast testing in the diagnostic evaluation of patients
with a suspected mitochondrial disorder (Cameron et al.
2004; van den Heuvel et al. 2004). Fibroblast OXPHOS
enzyme activities provide information that is helpful for the
selection of candidate genes for molecular genetic analysis,
even if enzyme activities are normal. For example, in
patients with reduced OXPHOS enzymes in muscle and
normal enzyme activities in fibroblasts, a genetic defect
might be present in one of the nuclear genes causing
mtDNA depletion, for example POLG (de Vries et al.
2007). It should be noted that normal enzyme activities
have also been observed in muscle of several POLG
patients (de Vries et al. 2008; Horvath et al. 2006; Van
Goethem et al. 2004). Biochemical observations in fibro-
blasts of patients with mtDNA mutations are variable. The
main reason for this is tissue/cell-type-specific differences
in heteroplasmy of mtDNA mutations. Although many
nuclear defects will give rise to reduced enzyme activities
in fibroblasts, there are several exceptions. In addition to
POLG, other nuclear genetic defects causing mtDNA
depletion syndromes, such as DGUOK and MPV17, often
show normal enzyme activities in fibroblasts (Mandel et al.
2001; Spinazzola et al. 2006). The combination of complex
I, III, IV, and/or V deficiency in muscle and normal
OXPHOS enzymes in fibroblasts is suggestive for involve-
ment of mtDNA depletion, deletions/rearrangements, or
point mutations (van den Heuvel et al. 2004). For mutations
in two aminoacyl-tRNA synthetase genes, DARS2 and
RARS2, normal or mild OXPHOS deficiencies in fibro-
blasts, respectively, have been reported, while for RARS2, it
has been shown that OXPHOS enzyme activities in muscle
vary from normal to severely reduced (Edvardson et al.
2007; Scheper et al. 2007). Fibroblast enzyme deficiencies
are common in nuclear defects of genes encoding structural
components and assembly factors of the OXPHOS system,
and also for defects in genes encoding proteins involved in
mitochondrial translation (Coenen et al. 2004; Miller et al.
2004; Saada et al. 2007; Smeitink et al. 2006). It should be
noted that a limited number of cases have been reported in
which a nuclear genetic defect of a structural respiratory
chain building block did not result in an enzyme deficiency
of the corresponding enzyme, e.g., complex I (Benit et al.
2001), complex II (Taylor et al. 1996), and complex IV
(Vesela et al. 2004), although according to the experiences
we have had in Nijmegen, these appear to be quite
exceptional cases. Occasionally, patients with normal
enzyme activities in muscle show reduced enzyme activities
in cultured fibroblasts, in particular for complex I and
PDHc (unpublished observations). Confirmation of enzyme
deficiencies in fibroblasts of the OXPHOS-deficient index
case in families in which the pathogenic genetic defect has
not (yet) been uncovered, is required before reliable
prenatal testing by measuring OXPHOS enzymes in
chorionic villi or amniocytes can be performed (Niers et
al. 2003). In Nijmegen, prenatal diagnosis is performed by
measuring respiratory chain or PDHc enzyme activities in
chorionic villi, provided that the diagnostic examination of
the index case has revealed a clearly detectable enzyme
deficiency in fibroblasts and muscle (or other tissue), and
that mtDNA mutations have been excluded in mtDNA from
a sample in which the enzyme deficiency has been detected
(Niers et al. 2003; Niers et al. 2001). When these
prerequisites are met, reliable prenatal diagnosis can be
performed. In addition to the diagnostic applications,
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fibroblasts provide a model system to study the pathogen-
esis of novel genetic defects, for example by performing
complementation experiments. Several assays have been
described to examine MEGS activities in cultured fibro-
blasts. These are based on the same principles as the MEGS
assays for fresh muscle. ATP synthesis, oxygen consump-
tion, and substrate oxidation rates can all be measured in
fibroblasts (Cameron et al. 2004; Rustin et al. 1994;
Wanders et al. 1993). In many of these assays, cells are
permeabilized with digitonin, which allows substrates,
ADP, and other assay ingredients to reach the mitochondria
and enter the matrix via the mitochondrial transporters. In
this way, mitochondrial ATP production, substrate oxida-
tion and respiration rates can be examined in a controlled
manner, providing additional information on the biochem-
ical phenotype of patients.
Avoiding potential pitfalls
Accurate diagnostic biochemical testing of tissue and cell
samples can be hampered by many different circumstances.
As with many other types of diagnostic laboratory tests, a
frequent cause for problems is sample collection and
handling, for example muscle samples that were thawed
during transport, or needle muscle biopsies contaminated
with lidocaine. In experienced diagnostic centers where
muscle biopsies are performed and analyzed on a daily
basis, these problems are not likely to occur. In addition to
these practical issues, there are also several other reasons
for difficulties in reaching a diagnosis by muscle biochemis-
try. These can include secondary mitochondrial dysfunction
arising from other metabolic defects, e.g., due to toxicity of
accumulating toxic metabolites, such as propionyl-CoA
(Schwab et al. 2006) or sulfide (Tiranti et al. 2009), or due
to drug effects, such as valproate (Haas et al. 1981). A
diagnosis can be missed when relying solely on a single
diagnostic test, e.g., biochemical testing of a muscle biopsy
in patients with hepatocerebral mtDNA depletion syndromes,
as outlined in the previous paragraph. Also, in the case of
mtDNA disorders, a normal muscle biochemistry can
sometimes be observed. This is usually due to a relatively
low percentage of heteroplasmy of the pathogenic mtDNA
mutation. For the m.3243G>A “MELAS” mutation, we have
shown that there are different thresholds for different
biochemical defects, such as complex I deficiency and
reduced ATP production rate (Janssen et al. 2008). In
practice, mtDNA analysis and muscle biochemistry are often
performed in parallel, as a normal biochemistry does not
exclude a mtDNA mutation, and vice versa, and, in addition,
as biochemical observations can be very helpful in the
interpretation of mtDNA sequence analysis results, especial-
ly when unknown mtDNA variants are encountered. In
general, most of the potential pitfalls mentioned here can be
avoided by performing a complete laboratory diagnostic
examination, including analysis of blood and urine metabo-
lites, muscle and fibroblast biochemistry, muscle histology,
mtDNA, and other candidate genes. The combined results of
these laboratory tests should be interpreted in the context of
the clinical phenotype of the patient (Haas et al. 2008).
Outlook
The number of mitochondrial proteins in mammals has
been estimated to be between 1,130 and 1,500 (Meisinger
et al. 2008; Pagliarini et al. 2008). To date, pathogenic
defects have been found in only a fraction of these proteins.
Given the number of genes encoding mitochondrial
proteins and the considerable subgroup of patients with a
mitochondrial disease phenotype in whom, despite new
developments in diagnostic testing, it is still not possible to
establish a definite diagnosis (Kirkman et al. 2008), it is
likely that more defects leading to a mitochondrial disorder
will be found in the mitochondrial proteome in the future.
The analysis of fresh muscle biopsies has led to the
identification of several genetic defects that are outside
the classical OXPHOS genetic defects. These include
defects in mitochondrial carriers, e.g., glutamate and
phosphate carriers (Mayr et al. 2007; Molinari et al. 2005;
Wibom et al. 2009). These studies have clearly demon-
strated the added value of fresh muscle sample analysis, as
it has guided the search for the specific genetic defects that
caused the observed biochemical abnormalities and clinical
phenotypes of the patients. It is likely that additional
pathogenic mitochondrial carrier defects will be found in
the future. To date, more than 20 different mitochondrial
functional carrier systems have been identified, and there
are many other carriers of which the exact function remains
to be established (Palmieri 2008). Genes encoding proteins
with a role in mitochondrial transcription and translation are
another likely group of candidate genes. These include the
mitochondrial aminoacyl-tRNA synthetases, in which only
two defects have been found thus far (Edvardson et al.
2007; Scheper et al. 2007). Several other groups of
candidate genes can be identified or postulated, including
those involved in mtDNA maintenance (Copeland 2008),
tRNA modification (Bykhovskaya et al. 2004), mitochon-
drial ribosomal assembly (Miller et al. 2004), nucleoid
formation (Hoffmann et al. 2009), enzymes regulating the
activity of key enzymes in the MEGS (Cameron et al. 2009;
Phillips et al. 2009), and several other cell biological
processes required for mitochondrial ATP production. For
all these mitochondrial defects, functional tests could have
an important added value in the biochemical diagnosis of
mitochondrial disorders in the future.
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In the near future, developments in next generation
sequencing technologies (Mardis 2008) will make it
possible to include high throughput sequence analysis in
the diagnostic work-ups of mitochondrial patients. The first
applications of this technology in mitochondrial diagnostics
have already been published (Vasta et al. 2009). In the case
of a suspected mitochondrial disorder, the number of
candidate genes that could be examined is quite large. For
example, for complex I there are more than 50 different
nuclear genes encoding for structural subunits and assembly
proteins, and many other genes of which it could be
postulated that a defect might lead to complex I deficiency.
Screening of this many genes using conventional sequenc-
ing techniques is an expensive and time-consuming effort.
Therefore, there is no doubt that high throughput molecular
genetic assays will increase the possibilities for diagnostic
testing of mitochondrial disorders in the near future. The
developments in genetic testing may change the role of
biochemical diagnosis. It can be expected that there will be
a greater demand for more detailed functional studies to
confirm the pathogenicity of new molecular genetic
variants. This is already the case for patients in with
unknown mtDNA variants detected by sequence analysis of
the mitochondrial genome, e.g., by mtDNA sequencing
arrays (van Eijsden et al. 2006). Nowadays, the complete
sequence analysis of the 16.5-kb mitochondrial genome is
routinely being performed in many diagnostic centers. Often,
the prediction of the pathogenicity of unknown genetic
variants is not possible on the basis of sequence information
alone. Usually, the level of heteroplasmy of the mtDNA
variant is checked in different tissues of the patient and, in
addition, in family members in the maternal lineage. Should
this not provide a clear answer to the question on pathogenic-
ity of mtDNA variants, functional testing of mtDNA variants
is possible by creating transmitochondrial cybrids (King and
Attardi 1989), in which the observed mitochondrial function
can provide additional diagnostic information. It is expected
that this problem of uncharacterized genetic variants will be
even greater for results of high throughput nuclear genomic
sequencing data. In a recent study in which 362 genes were
sequenced in two patients (Vasta et al. 2009), it was found
that, after extensive bioinformatical analysis of all genetic
variants that were identified, two to three genetic variants
remained for which it was not possible to predict possible
pathogenicity without follow-up functional testing. It is
likely that these figures will improve in time, as bioinfor-
matical tools will improve in time and databases are
continuously being filled with new genetic variants. Never-
theless, there will be an increasing demand for a more
detailed functional analysis of individual genetic variants, in
order to confirm the diagnosis in individual patients. The
combination of a sophisticated bioinformatical approach with
detailed functional analysis of individual proteins and path-
ways will be required to unravel the mechanisms behind
protein malfunction and pathogenesis of mitochondrial
disorders (Huynen et al. 2009). In addition, detailed
information on the biochemical phenotype prior to high
throughput genetic testing will be of benefit to the selection of
groups of candidate genes and to bioinformatical evaluation of
genetic variants. For example, in the case of a proven complex
I deficiency, the high-throughput genetic examination could
focus on complex I genes. Therefore, the biochemical
evaluation of mitochondrial functional state will continue to
play an important role in the diagnostic examination of
mitochondrial patients in the foreseeable future.
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